Authors
Loading...
Functional assays reveal metabolic reprogramming drives drug resistance in AML, highlighting the role of FGF11 and HIF-1α.
Lv et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: